To order this 370+page report, which features 90+ figures and 110+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
Key Market Insights
§ With two approveddrugs and close to 300 clinical / preclinical product candidates, thebispecific antibody therapeutics pipeline has evolved significantly over thepast few years
§ The pipeline featuresdrug candidates that target a wide range of biological antigens based ondifferent antibody formats through novel mechanisms of action; more than 50% ofthese act by retargeting or activation of T-Cells
§ To gain a competitiveedge in the market, developers are actively exploring novel biological targetsand mechanisms of action to treat diverse disease indications
§ Although start-upsand mid-sized firms are spearheading the innovation, several big pharmaceuticalcompanies are also actively engaged
§ In order to cater tothe evolving needs of developers, technology providers have establishedpresence across different regions; the US and EU have emerged as the key hubs
§ Close to 50,000patients were estimated to have been enrolled in clinical trials evaluatingbispecific antibody therapeutics, across various geographical locations andphases of development
§ The increasinginterest of stakeholders in this domain can also be gauged by the risingproduct development / commercialization, R&D and technology licensing dealsbeing signed across various regions
§ Given thecomplexities associated with the development of bispecific antibodies, contractorganizations have become an indispensable part of the development andmanufacturing process of antibody therapeutics
§ In order to keeppatients and healthcare professionals informed and aware of the developments,companies are deploying diverse promotional strategies for their respectiveproducts
For more information,please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
